Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Hepatitis D

Therapeutic area intelligence for Hepatitis D with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Assets

Recent signals(2)

StrategyJuly 14, 2026

Roche launches first fully automated cobas HDV test for Hepatitis D diagnosis

Roche has introduced the cobas HDV test, the first fully automated diagnostic solution for Hepatitis D Virus.

CompetitiveJuly 14, 2026

Roche Launches First Fully Automated HDV Test to Enhance Diagnosis and Monitoring

Roche has introduced the cobas HDV test, the first fully automated diagnostic solution for Hepatitis D Virus, enhancing diagnosis and treatment monitoring.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Hepatitis D →

Infectious Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.